Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) shares were down 0.9% on Friday . The company traded as low as $9.88 and last traded at $10.10, with a volume of 1,880,249 shares trading hands. The stock had previously closed at $10.19.

A number of research analysts have recently weighed in on ARIA shares. JMP Securities reaffirmed a “buy” rating on shares of Ariad Pharmaceuticals in a research report on Monday, June 6th. Cowen and Company reissued a “buy” rating and issued a $10.00 price target on shares of Ariad Pharmaceuticals in a report on Monday, June 6th. William Blair reissued a “buy” rating and issued a $10.00 price target on shares of Ariad Pharmaceuticals in a report on Tuesday, May 24th. Jefferies Group reissued a “buy” rating and issued a $13.00 price target on shares of Ariad Pharmaceuticals in a report on Tuesday, May 24th. Finally, Zacks Investment Research raised Ariad Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a report on Tuesday, July 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $9.19.

The stock’s market cap is $1.95 billion. The stock has a 50 day moving average of $9.57 and a 200 day moving average of $7.66.

Ariad Pharmaceuticals (NASDAQ:ARIA) last announced its quarterly earnings data on Thursday, July 28th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.70. The firm earned $65.30 million during the quarter, compared to analyst estimates of $60.64 million. During the same period in the prior year, the company posted ($0.28) earnings per share. The firm’s revenue for the quarter was up 133.0% on a year-over-year basis. Equities analysts predict that Ariad Pharmaceuticals Inc. will post ($0.09) earnings per share for the current fiscal year.

In related news, Director Athanese Lavidas sold 76,250 shares of the firm’s stock in a transaction dated Wednesday, June 15th. The stock was sold at an average price of $8.21, for a total transaction of $626,012.50. Following the sale, the director now directly owns 141,631 shares of the company’s stock, valued at $1,162,790.51. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Massimo Radaelli sold 108,569 shares of the firm’s stock in a transaction dated Tuesday, June 14th. The stock was sold at an average price of $8.25, for a total value of $895,694.25. Following the sale, the director now directly owns 128,088 shares in the company, valued at $1,056,726. The disclosure for this sale can be found here.

ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.